Opendata, web and dolomites

G125 SIGNED

A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 G125 project word cloud

Explore the words cloud of the G125 project. It provides you a very rough idea of what is the project "G125" about.

content    permanent    debilitating    underlying    regurgitation    patients    ppis    procedure    vascular    option    ingrowth    disease    efs    outpatient    gastroesophageal    reflux    intervention    innovation    chain    flexible    treatment    root    proton    clinical    bore    cell    drafted    acid    responders    treat    million    15    transition    perform    injectable    anti    refine    area    integrity    g125    invasive    severe    barrier    endoscopic    thereby    needle    unfortunately    people    ascentx    medical    esophageal    medications    pmma    sphincter    stimulated    12    consists    fibro    supply    gastroenterological    made    elongated    prepare    disorder    lower    biocompatible    digestive    syringe    mask    normal    diagnosis    enzymes    plan    collagen    polymethylmethcrylate    bovine    surgical    gastric    gerd    commercialization    microspheres    daily    injection    bulking    inhibitors    suspended    least    union    trial    strategy    agent    cure    heartburn    esophagal    catheter    pump    sufferers    market    symptoms    gastro    medication    scaffold    caused    les    uses    followed    20    tissue   

Project "G125" data sheet

The following table provides information about the project.

Coordinator
ASCENTX MEDICAL EUROPE LIMITED 

Organization address
address: UNIT 6 QUEENS YARD, WHITE POST LANE
city: LONDON
postcode: E95EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://ascentxmedical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASCENTX MEDICAL EUROPE LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Gastroesophageal Reflux Disease (GERD) is a digestive disorder associated with symptoms such as heartburn and regurgitation, and reflux of normal gastric content like gastric acid and digestive enzymes. GERD is caused by a loss of integrity of the gastro-esophageal barrier known as the 'lower esophageal sphincter' (LES). This condition is one of the most common gastroenterological diagnosis in the European Union, with an estimated 15-20 Million daily sufferers. GERD today is typically treated with medications such as proton pump inhibitors (PPIs). Unfortunately, these anti-acid medications only ‘mask’ GERD symptoms, cause severe side-effects long-term, and about 20% of patients are non-responders. Importantly, they do not treat/cure the underlying root cause of acid reflux. For people who have severe GERD and do not respond to medication, invasive surgical intervention remains the only option. G125 is the least invasive outpatient treatment for Gastroesophageal Reflux Disease (GERD). It is a permanent injectable bulking agent for the endoscopic treatment which enables cell growth in the Lower Esophagal Sphincter (LES), thereby providing long term cure for the debilitating symptoms of GERD. G125 uses a tissue-friendly (biocompatible) microspheres made of Polymethylmethcrylate (PMMA) suspended in bovine collagen and an Elongated Flexible Syringe (EFS) which consists of an elongated catheter and a transition bore needle. The PMMA microspheres provide a permanent scaffold for stimulated fibro-vascular tissue ingrowth in the affected area. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project AscentX Medical will refine the endoscopic injection procedure, perform a 12 month clinical trial with 60 patients followed by a scale up of the production to prepare for commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "G125" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "G125" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More  

Osto.Me (2020)

Ostomy Market Disruption: First Leak Proof Ostomy Appliance removing the need for Accessories in the Ostomy Market

Read More